Focus on Anticoagulation Care

Back to articles

Evaluating apixaban as an option for patients with severe renal impairment

KEY POINT

No significant differences were observed in rates of major bleeding, composite bleeding, or stroke with use of apixaban (Eliquis—Bristol-Myers Squibb) compared with warfarin in patients with severe renal impairment, according to results of a small retrospective analysis published online in Pharmacotherapy.